HEB stock forecast
Our latest prediction for Hemispherx Biopharma, Inc.'s stock price was made on the June 27, 2019 when the stock price was at 4.39$.
In the short term (2weeks), HEB's stock price should outperform the market by 5.70%. During that period the price should oscillate between -12.83% and +24.99%.
In the medium term (3months), HEB's stock price should underperform the market by -0.60%. During that period the price should oscillate between -27.30% and +54.25%.Get email alerts
About Hemispherx Biopharma, Inc.
Hemispherx Biopharma, Inc. operates as a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Orlando, FL.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -9.68$ per share.
The book value per share is 0.19$
Three months stock forecastJune 27, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|